Compare · BSX vs MMSI
BSX vs MMSI
Side-by-side comparison of Boston Scientific Corporation (BSX) and Merit Medical Systems Inc. (MMSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and MMSI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.16B, about 18.8x MMSI ($3.85B).
- Over the past year, BSX is down 51.1% and MMSI is down 30.2% - MMSI leads by 20.8 points.
- MMSI has been more active in the news (15 items in the past 4 weeks vs 12 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 15 for MMSI).
- Company
- Boston Scientific Corporation
- Merit Medical Systems Inc.
- Price
- $48.97+0.83%
- $66.14+2.53%
- Market cap
- $72.16B
- $3.85B
- 1M return
- -13.46%
- +6.21%
- 1Y return
- -51.05%
- -30.25%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 15
- Recent ratings
- 25
- 15
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Merit Medical Systems Inc.
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest MMSI
- CHIEF LEGAL OFFICER, SECRETARY Lloyd Brian G. gifted 2,000 shares, decreasing direct ownership by 3% to 60,132 units (SEC Form 4)
- SEC Form SD filed by Merit Medical Systems Inc.
- Director Gunderson Thomas J. exercised 21,250 shares at a strike of $52.17, increasing direct ownership by 54% to 60,741 units (SEC Form 4)
- Director Ward Lynne N. was granted 3,457 shares, increasing direct ownership by 44% to 11,266 units (SEC Form 4)
- Director Ward Scott R. was granted 3,457 shares (SEC Form 4)
- Director Gunderson Thomas J. was granted 3,457 shares, increasing direct ownership by 10% to 39,491 units (SEC Form 4)
- Director Evans Stephen C. was granted 3,457 shares, increasing direct ownership by 51% to 10,266 units (SEC Form 4)
- Director Kaiser Laura S. was granted 3,457 shares, increasing direct ownership by 35% to 13,352 units (SEC Form 4)
- Director Perez Silvia M. was granted 3,457 shares, increasing direct ownership by 75% to 8,040 units (SEC Form 4)
- Director Carpenter Lonny J. was granted 3,457 shares, increasing direct ownership by 20% to 20,824 units (SEC Form 4)